Orphan Synergy Europe - Pharma News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.01.16	OSE Pharma Announces Initiation of Its Pivotal Phase 3 Trial of Tedopi® in Non-Small Cell Lung Cancer (Businesswire)
05.01.16	OSE Pharma Announces Its Events for Q1 2016 (Businesswire)
23.12.15	OSE Pharma Announces Selection of 70 International Clinical Centers to Participate in Its Pivotal Phase 3 Trial of Tedopi® for Patients Diagnosed with Advanced Non-Small Cell Lung Cancer (NSCLC) (Businesswire)
14.12.15	OSE Pharma to Participate to Biotech Showcase™ During JP Morgan Healthcare Conference (Businesswire)
07.12.15	OSE Pharma Admitted to Long-Only Deferred Settlement Service (Businesswire)
19.11.15	OSE Pharma Successfully Completes the Manufacturing of the Clinical Batches for Its Pivotal Phase 3 Clinical Trial with Tedopi® (Businesswire)
02.11.15	OSE Pharma receives positive opinion from several European countries to start pivotal Phase 3 trial of Tedopi® (Businesswire)
20.10.15	OSE Pharma to attend BIO-Europe 2015 (Businesswire)
29.09.15	OSE Pharma to participate to the Large & Midcap Event in Paris on October 7-8, 2015 (GlobeNewswire)
16.09.15	OSE Pharma Enters Euronext Index CAC® Small, CAC® Mid & Small and CAC® All-Tradable (Businesswire)
14.09.15	Ose Pharma to Attend BioPharm America September 15th to 16th, 2015, Boston, United-States (Businesswire)
10.09.15	OSE Pharma SA: Results for the First Half of 2015 in Line with Forecasts and Major Clinical Advances (Businesswire)
09.09.15	OSE PHARMA unveils Clinical and immunological outcomes in patients with brain metastases treated with Tedopi® in a phase 2 trial presented at the World Conference on Lung Cancer (WCLC) in Denver, USA (Businesswire)
01.09.15	OSE Pharma Sets up Scientific Steering Committee and Takes a First Step in the Launch of Its Phase 3 Trial in Lung Cancer (Businesswire)
23.07.15	OSE Pharma SA : Presentation of Tedopi’s Clinical Trial Data for Patients with Brain Metastasis Treated Due to Lung Cancer at the 16th World Conference on Lung Cancer (Businesswire)
15.06.15	OSE Pharma to attend "French Life Science Days” June 17th to 18th 2015, New York (Businesswire)
08.06.15	OSE Pharma to Participate to BIO INTERNATIONAL CONVENTION (Businesswire)
28.05.15	OSE Pharma and Simbec-Orion to participate in the 51st annual Meeting of the American Society of Clinical Oncology, May 29th to June 2nd 2015, Chicago (Businesswire)
11.05.15	OSE Pharma to partner Tedopi® with RAFA laboratories for long term licensing and distribution agreement in Israel (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swisscom	541.00	0.84 %	K V
Nestle	85.80	0.72 %	K V
Givaudan	4’020.00	0.65 %	K V
Lonza Grp	573.40	0.49 %	K V
Roche Hldg G	255.60	0.43 %	K V
Kuehne+Nagel Int	191.40	-0.26 %	K V
Geberit	599.00	-0.27 %	K V
Holcim	97.58	-0.61 %	K V
Sika	218.90	-0.77 %	K V
CieFinRichemont	152.90	-1.67 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Orphan Synergy Europe - Pharma Aktie VALOR 25507187 / ISIN FR0012127173

Nachrichten zu Orphan Synergy Europe - Pharma SA

Aktien Top/Flop

Meistgelesene Nachrichten